Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov 19;81(21 Suppl 1):S15-24.
doi: 10.1212/01.wnl.0000435745.95155.b8.

Functional outcome measures for NF1-associated optic pathway glioma clinical trials

Michael J Fisher  1 , Robert A Avery, Jeffrey C Allen, Simone L Ardern-Holmes, Larissa T Bilaniuk, Rosalie E Ferner, David H Gutmann, Robert Listernick, Staci Martin, Nicole J Ullrich, Grant T Liu; REiNS International Collaboration
Affiliations

Functional outcome measures for NF1-associated optic pathway glioma clinical trials

Michael J Fisher et al. Neurology. .

Abstract

Objective: The goal of the Response Evaluation in Neurofibromatosis and Schwannomatosis Visual Outcomes Committee is to define the best functional outcome measures for future neurofibromatosis type 1 (NF1)-associated optic pathway glioma (OPG) clinical trials.

Methods: The committee considered the components of vision, other ophthalmologic parameters affected by OPG, potential biomarkers of visual function, and quality of life measures to arrive at consensus-based, evidence-driven recommendations for objective and measurable functional endpoints for OPG trials.

Results: Visual acuity (VA) assessments using consistent quantitative testing methods are recommended as the main functional outcome measure for NF1-OPG clinical trials. Teller acuity cards are recommended for use as the primary VA endpoint, and HOTV as a secondary endpoint once subjects are old enough to complete it. The optic disc should be assessed for pallor, as this appears to be a contributory variable that may affect the interpretation of VA change over time. Given the importance of capturing patient-reported outcomes in clinical trials, evaluating visual quality of life using the Children's Visual Function Questionnaire as a secondary endpoint is also proposed.

Conclusions: The use of these key functional endpoints will be essential for evaluating the efficacy of future OPG clinical trials.

Trial registration: ClinicalTrials.gov NCT00879034.

PubMed Disclaimer

Figures

Figure
Figure. Visual acuity testing methods
(A) Teller acuity cards, (B) Lea, (C) HOTV, (D) Snellen.
See this image and copyright information in PMC

References

    1. Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007;61:189–198 - PMC - PubMed
    1. Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997;86:747–754 - PubMed
    1. Ater J, Holmes E, Zhou T, et al. Abstracts from the thirteenth international symposium on pediatric neuro-oncology: results of COG protocol A9952- a randomized phase 3 study of two chemotherapy regimens for incompletely resected low-grade glioma in young children. Neuro Oncol 2008;10:451
    1. Prados MD, Edwards MS, Rabbitt J, Lamborn K, Davis RL, Levin VA. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol 1997;32:235–241 - PubMed
    1. Campagna M, Opocher E, Viscardi E, et al. Optic pathway glioma: long-term visual outcome in children without neurofibromatosis type-1. Pediatr Blood Cancer 2010;55:1083–1088 - PubMed

Publication types

Associated data